We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Silicon Chip Based Blood Test Rapidly Diagnoses Patients with Hypothyroidism

By LabMedica International staff writers
Posted on 29 Jul 2024

Hypothyroidism impacts about 10% of the U.S. population, making the Thyroid Stimulating Hormone (TSH) test the most frequently conducted immunoassay in the United States. Traditional testing often involves significant time commitments for patients, including visits to labs and waiting 2 to 5 days for results. Now, a new TSH immunoassay performed on a silicon chip delivers results in approximately 30 minutes.

Genalyte (San Diego, CA, USA) has received U.S. Food and Drug Administration (FDA) approval for its groundbreaking immunoassay, the first of its kind to be cleared for use on a silicon chip-based device. The Maverick Diagnostic System (MDS) incorporates silicon chip-based photonic ring resonator technology, enabling the execution of multiple rapid tests simultaneously from a small sample of whole blood or serum. This system is also connected to the cloud, facilitating the retrieval of assay protocols and enabling clinical oversight. Genalyte’s innovation effectively minimizes the traditional bulky lab machinery to 3% of its original size while still delivering lab-quality results.

The compact Maverick Diagnostic System, comparable in size to a small microwave and weighing just 30 pounds, offers lab-quality results on-site, representing a significant shift in laboratory processing much like the transformation brought by silicon chips in computing. This technology promises to significantly reduce the turnaround time for lab results by 98%, potentially making it available at point-of-care locations in the future. This FDA clearance not only marks a critical achievement for Genalyte but also for the diagnostic industry, confirming the company’s capability to deliver precise and rapid lab results.

“This TSH assay is a powerful tool to rapidly diagnose patients and get them on a path to treatment quicker,” said CEO of Genalyte Ashraf Hanna, Ph.D., M.D. “This technology is groundbreaking for immunoassay development which hasn’t changed conceptually since 1959. The Maverick has the potential to allow a broad menu of blood testing in a small, portable device at the point of care.”

Related Links:
Genalyte

New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Dehydroepiandrosterone Assay
DHEA ELISA
New
Treponema Pallidum Test
ZEUS IFA Fluorescent Treponemal Antibody-Absorption (FTA-ABS) Test System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2025 Globetech Media. All rights reserved.